spacer
home > pmps > autumn 2018 > thermal fluid selection
PUBLICATIONS
Pharmaceutical Manufacturing and Packing Sourcer

Thermal Fluid Selection

Across all processing and manufacturing industries, the choice of heat transfer fluid is critical for ensuring high efficiency of heat transfer systems. When doing so, one must be aware of the key considerations when choosing a heat transfer fluid for a pharmaceutical processing plant.

Purchasing is now much easier than writing and posting a cheque or counting and double-checking cash. Amazon orders can be placed by a touch of a button and in-store purchases can be made with a flash of a contactless card. Even in business, purchasing is easier than it used to be. However, it should still be carefully thought through first. Engineers often think that all they need to consider when choosing a fluid for their heat transfer system are the financial aspects, but many other factors, if not thought through, can have costly and damaging consequences for businesses. In pharmaceutical plants, the requirement for compliance with regulations that ensure the health and safety of consumers, as well as the efficacy of the product, mean additional factors must be considered when choosing a heat transfer fluid.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Dr Chris Wright is a Research Scientist at Global Heat Transfer and holds a BSc and a PhD from the University of Leeds, UK. His research focusses on the use and maintenance of heat transfer fluids in manufacturing and processing, including specialist chemicals, food, pharmaceutical, and solar sectors.
spacer
Dr Chris Wright
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Sphere Fluidics hires 10 new UK and US staff in its plan to scale internationally

Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, announced today that it has appointed six new employees and plans to hire four more staff in its UK and US sites. Rob Treanor and Andrew Campbell join Sphere Fluidics as Director of Operations and Director of Finance, respectively alongside new hires to its sales, operations and scientific teams. These appointments will expand the Company’s commercial capabilities and facilitate service and support for new and existing Cyto-Mine® customers in both the UK and US.
More info >>

White Papers

Working Towards a Standardised Identification Solution

PCI Pharma Services

The security of the pharmaceutical supply chain is an issue of growing concern, with recent reports addressing its vulnerability to counterfeiting. The complexity of the European supply chain is one of the key factors of this counterfeiting pandemic, with millions of medicine packs being moved around the EU, annually. Aside from this, fragmentation has resulted in decreased transparency in the supply chain and increased difficulties to track and trace medicines, leading to significant threat from counterfeiting. As a key source of income for the European economy, it is essential that the supply chain remains safe and free of counterfeits. A significant stumbling block within the industry remains to be the lack of a unified, single‐source pan‐European or indeed global database where scanned bar codes on drug packaging can be verified at point of dispense. At some point in the future the pharmaceutical industry, regulatory bodies, clinicians and retailers will need to join forces to overcome this.
More info >>

 
Industry Events

Highly Potent Active Pharmaceutical Ingredients (HPAPI)

13-14 May 2019, Copthorne Tara Hotel, London, UK

SMi is delighted to announce its 3rd Annual Highly Potent Active Pharmaceutical Ingredients conference coming to London on the 13th-14th May 2019. The HPAPI global market has developed rapidly in the past year and is continuing to expand into the future, with over a quarter of drugs in development worldwide being classified as highly potent. As a result, there is a growing demand for both pharmaceutical and contracted manufacturers to adapt to the evolving HPAPI landscape.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement